IL-27 - a double agent in the IL-6 family
| Autor: | Gareth W. Jones, Simon Arnett Jones, Anna Cardus, David Hill |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Stromal cell Myeloid medicine.medical_treatment Immunology Inflammation Adaptive Immunity Polymorphism Single Nucleotide Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine medicine Immunology and Allergy Humans Interleukin 6 Review Articles biology business.industry Interleukin-6 Interleukins Lymphokine Interleukin Acquired immune system Immunity Innate 030104 developmental biology Cytokine medicine.anatomical_structure biology.protein medicine.symptom business 030215 immunology Signal Transduction |
| ISSN: | 0009-9104 |
| Popis: | Summary The cytokine interleukin (IL)-6 is a major therapeutic target for the treatment of various inflammatory and autoimmune diseases. While IL-6 receives considerable attention in studies of innate and adaptive immunity, the IL-6-related family member IL-27 is recognized increasingly for its effects on cellular proliferation, differentiation and leucocyte effector functions. Both cytokines activate responses in myeloid and stromal tissue cells, where they direct the transition from innate to adaptive immunity. However, they are identified frequently as lymphokines that control responses in T cells and B cells. In this regard, IL-27 often opposes the action of IL-6. Here, we will review the role of IL-6 and IL-27 in inflammation, with a particular focus on inflammatory arthritis, and discuss their importance in the diagnosis, stratification and treatment of autoimmune disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text